Evidence map›Paper›PMID 41035410›Full record

ArticleHaematologica2026

Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.

Dina Nienke Lokhorst, Yolba Smit, Bart J F Van den Bemt, Rosella P M G Hermens, Marten R Nijziel, Asiong K-S Jie, Laura G M Daenen, Saskia K Klein, Eduardus F M Posthuma, Peter E Westerweel and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dina Nienke LokhorstRadboud University medical center, Department of Hematology, Nijmegen, Gelderland.
Yolba SmitRadboud University medical center, Department of Hematology, Nijmegen, Gelderland.
Bart J F Van den BemtSint Maartenskliniek, Department of Pharmacy, GM, Nijmegen, Gelderland, the Netherlands; Radboud University medical center, Department of Pharmacy, pharmacology and toxicology, Nijmegen, Gelderland.
Rosella P M G HermensRadboud University medical center, Science Department IQ Health, Nijmegen, Gelderland.
Marten R NijzielCatharina Hospital Eindhoven, Catharina Cancer Institute, Department of Hematooncology Eindhoven, Noord-Brabant.
Asiong K-S JieZuyderland MC, Department of Internal Medicine, Sittard-Geleen, Limburg.
Laura G M DaenenUniversity Medical Center Utrecht, Department of Hematology, Utrecht, Utrecht.
Saskia K KleinUniversity Medical Center Groningen, Department of Hematology, Groningen, Groningen.
Eduardus F M PosthumaReinier de Graaf Hospital, Department of Internal Medicine, Delft, Zuid-Holland.
Peter E WesterweelAlbert Schweitzer Hospital, Department of Internal Medicine, Dordrecht, Zuid-Holland.
Marjolein DonkerAmsterdam University Medical Center, Department of Hematology, Amsterdam, Noord-Holland.
Mels HoogendoornFrisius Medical Center Leeuwarden, Department of Internal Medicine, Leeuwarden, Friesland.
Charlotte L BekkerRadboud University medical center, Department of Pharmacy, pharmacology and toxicology, Nijmegen, Gelderland. charlotte.bekker@radboudumc.nl.
Nicole M A BlijlevensRadboud University medical center, Department of Hematology, Nijmegen, Gelderland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-guided dose reduction, as explored in the RODEO study, offers a promising approach to alleviate the burden of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML). Supported by shared decision-making (SDM) and a patient decision aid, this strategy aims to reduce TKI toxicity while maintaining effectiveness. This interim analysis evaluates its effectiveness at six months, focusing on intervention failure, i.e., TKI dose re-escalation due to loss of major molecular remission (MMR) of BCR::ABL1 (>0.1%IS) or expected loss of MMR, and patient-reported health-related quality of life (HRQoL) and symptom burden. The SDM-process and decisional conflict are also evaluated. This is a prospective, single-arm, multicenter trial including 148 patients with chronic-phase CML in at least MMR. Patients and their treating hematologists were engaged in an SDM-process and selected a reduced TKI dose. BCR::ABL1 monitoring was conducted regularly; HRQoL and symptom burden was assessed using the scores of the QLQ-C30 and QLQ-CML24 questionnaires, and IL 156 item list. of the European Organisation for Research and Treatment of Cancer (EORTC). SDM and decisional conflict were evaluated via SDM-Q-9, SDM-Q-Doc, and the Decisional Conflict Scale. Of 146 patients analyzed, 2.8% experienced intervention failure at six months. Modest statistically significant improvements were seen in multiple symptom scales. SDM was well-evaluated, with low decisional conflict by patients. Patient-guided dose reduction appears safe and beneficial at six months follow-up.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdultAgedFemaleFusion Proteins, bcr-ablHumansMaleMiddle AgedProspective StudiesQuality of LifeTyrosine Kinase InhibitorsYoung AdultFusion Proteins, bcr-ablProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Identifiers

PMID41035410
PMCPMC12951149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.